Jnana co-founders Joanne Kotz (L) and Joel Barrish
Roche doubles down on Jnana's drug discovery platform, kicking off second deal with $50M cash — while biotech bags $107M
Whatever Roche has learned about Jnana Therapeutics’ drug discovery platform over the past two years, it’s intrigued enough to set up a second partnership.
While the last deal had centered on solute carriers — or SLCs, the huge family of proteins that Jnana had built its name on — this time around, Roche wants to apply Jnana’s tech on a range of other hard-to-drug targets. The pharma giant will dish out $50 million upfront, plus “significant near-term milestone payments” and more than $2 billion in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
